Effect of Low-Dose Rivaroxaban Plus Aspirin on 18F-FDG PET/CT-Detectable Carotid Plaque Inflammation: A Randomised Trial

Clicks: 1
ID: 320888
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #86 of 96 articles by views in European Heart Journal - Cardiovascular Imaging

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: Aspirin plus low-dose rivaroxaban reduces cardiovascular events in stable atherosclerosis; its effect on arterial inflammation in humans remains unclear. We tested whether adding low-dose rivaroxaban to aspirin reduces 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)-detectable carotid plaque inflammation. METHODS AND RESULTS: In this single-centre, randomised, open-label, proof-of-concept trial with blinded endpoint assessment, adults with asymptomatic carotid stenosis (20%-80%) and elevated carotid FDG uptake (target-to-background ratio [TBR] ≥ 1.6) were assigned 1:1 to aspirin (100 mg/day) plus rivaroxaban (2.5 mg twice daily) or aspirin alone. The primary endpoint was percent change in the most diseased segment (MDS) TBR of the index carotid artery at 12 months. Secondary endpoints included whole-vessel carotid TBR, aortic TBR, lipid and high-sensitivity C-reactive protein (hsCRP) changes. From September 2021 to December 2023, 92 patients were randomised (mean age 69.4 years; 88% men), and 81 (88%) completed paired imaging. Mean percent changes in MDS TBR were -7.25% (95% confidence interval [CI], -11.03 to -3.48) with combination therapy and -7.36% (95% CI, -11.06 to -3.67) with aspirin alone (adjusted between-group difference, -1.50 percentage points, 95% CI, -6.20 to 3.21; P = 0.529). Secondary imaging endpoints were concordant. Laboratory parameters were similar, except for a nominal hsCRP difference without multiplicity adjustment. Minor bleeding occurred in four (8.7%) and one (2.2%) patients, respectively; no major bleeding or deaths occurred. CONCLUSIONS: In patients with carotid atherosclerosis, adding low-dose rivaroxaban to aspirin did not produce a detectable incremental reduction in 18F-FDG PET/CT-assessed carotid plaque inflammation compared with aspirin alone over 12 months.
Reference Key
openalex_W7168121488 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tae Oh Kim, Sangwon Han, Jeongryul Ryu, Jung-Bok Lee, Chong Hyun Suh, Seong-Bong Wee, Soo‐Jin Kang, Dae Hyuk Moon, Cheol Whan Lee, Jun Gyo Gwon, Seung‐Whan Lee
Journal European Heart Journal - Cardiovascular Imaging
Year 2026
DOI
10.1093/ehjci/jeag176
URL
https://doi.org/10.1093/ehjci/jeag176
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.